Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971669 | PMC |
| http://dx.doi.org/10.1001/jamanetworkopen.2025.3158 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trends in XTAMPZA ER and other oxycodone misuse and abuse during COVID-19: A mosaic approach.
J Opioid Manag
September 2025
Rocky Mountain Poison and Drug Safety, Denver Health and Hospital Authority, Denver, Colorado. ORCID: https://orcid.org/0000-0001-5989-9354.
Despite efforts to reduce abuse, opioids remain a societal concern. Coronavirus disease 2019 (COVID-19) brought new challenges, and research is needed to understand its impact on opioid abuse in the population. Three data sources were used to investigate trends in misuse and abuse of XTAMPZA® ER compared to extended-release (ER) and single-entity immediate-release (SE-IR) oxycodone from 2019Q3 through 2022.
View Article and Find Full Text PDFDrug Shortages for Prescription Amphetamine Derivatives.
J Pediatr Pharmacol Ther
April 2025
Georgetown University School of Medicine (MS, MMA), Washington, DC.
Objective: Amphetamine derivatives are first-line medications for attention-deficit/hyperactivity disorder (ADHD). Recently, there have been increasing reports of drug shortages involving amphetamine derivatives. The objective of this study is to describe trends in drug shortages impacting prescription amphetamine derivatives.
View Article and Find Full Text PDFTreatment initiations and opioid overdoses among recently incarcerated people after adoption of the take-home methadone policy.
Drug Alcohol Depend
September 2025
Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Opioid overdose is the leading cause of death among recently incarcerated people. Take-home methadone flexibilities adopted at the COVID-19 pandemic's outset may have facilitated opioid use disorder treatment initiations and prevented opioid overdoses for this population. These flexibilities may have particularly enhanced treatment initiations for rural residents, given relaxed in-person methadone treatment requirements.
View Article and Find Full Text PDFEffects of Pemafibrate on Cholesterol Synthesis and Absorption: a Post-Hoc Subgroup Analysis of a Phase 2 Clinical Trial.
J Atheroscler Thromb
May 2025
Division of Endocrinology and Metabolism, Department of Internal Medicine, School of Medicine, Jichi Medical University.
Aim: Recently, we reported that a pemafibrate extended-release (XR) formulation lowered low-density lipoprotein cholesterol (LDL-C) and cholesterol synthesis and absorption markers in a phase 2 clinical pharmacology study. Here we describe our post-hoc analysis of that study, discuss the mechanism by which pemafibrate lowers LDL-C, and suggest which patients may respond favorably to pemafibrate treatment.
Methods: In the phase 2 study, patients with hypertriglyceridemia received treatment with pemafibrate immediate-release (IR) 0.
Trends in Outpatient Buprenorphine Prescribing for Chronic Pain: A Retrospective Analysis Over 18 Months.
Psychopharmacol Bull
April 2025
Varrassi, Department of Research, Fondazione Paolo Procacci, Rome, ITA.
Background: Buprenorphine, a partial opioid agonist, has gained attention for its use in chronic pain management due to its lower risk of abuse and respiratory depression compared to traditional opioids. The utilization of buprenorphine for chronic pain has increased in recent years. This study aimed to analyze trends in buprenorphine prescribing for chronic pain in an outpatient setting over an 18-month period, excluding buprenorphine-naloxone combinations used for opioid use disorder and opioid dependence.
View Article and Find Full Text PDF